Figure 2.

(a) Onset and (b) duration of Pyrexia TEAEs in the Placebo-controlled UC cohort.

^a‘Ongoing’ included patients whose TEAE outcomes were unknown.

n1, number of events per timepoint; N1, total number of AEs by treatment group; TEAE, treatment-emergent adverse event; UC, ulcerative colitis.